Vimovo® (esomeprazole magnesium/naproxen) – New and expanded indications
July 6, 2017 – The FDA approved Horizon Pharmaceuticals’ Vimovo (esomeprazole magnesium/naproxen) delayed-release tablets, in adults and adolescent patients ≥ 12 years of age weighing ≥ 38 kg, requiring naproxen for symptomatic relief of arthritis and esomeprazole magnesium to decrease the risk for developing naproxen-associated gastric ulcers; and the naproxen component of Vimovo is indicated for relief of signs and symptoms of juvenile idiopathic arthritis (JIA) in adolescent patients.
Top